The Cost Burden of Multiple Sclerosis in the United States (US): A Systematic Review of the Literature (P03.207)

CONCLUSIONS: MS is a costly chronic disease, with high average direct and indirect costs per patient/year. Further research is needed to better understand: costs by MS type, costs associated with increasing disability and early retirement, and the potential impact of new treatments expected to launch in the coming years.Supported by: F. Hoffmann-La Roche Ltd.Disclosure: Mr Adelman has received personal compensation for activities with Genentech, Inc. as an employee. Dr. Rane has received personal compensation for activities with Genentech Inc. as an employee. Dr. Rane holds stock options in Genentech Inc. Ms. Villa has received personal compensation for activites with Genentech, Inc. as an employee.
Source: Neurology - Category: Neurology Authors: Tags: P03 Multiple Sclerosis: Cost and Impact of MS Care Source Type: research